KR20020046615A - Skin whitening composition containing arctium lappa extracts - Google Patents
Skin whitening composition containing arctium lappa extracts Download PDFInfo
- Publication number
- KR20020046615A KR20020046615A KR1020000076871A KR20000076871A KR20020046615A KR 20020046615 A KR20020046615 A KR 20020046615A KR 1020000076871 A KR1020000076871 A KR 1020000076871A KR 20000076871 A KR20000076871 A KR 20000076871A KR 20020046615 A KR20020046615 A KR 20020046615A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- whitening agent
- propanol
- allium
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 우엉(Arctium lappa)의 열매로부터 분리 정제한 우방자추출물을 함유하는 미백제에 관한 것이다.The present invention relates to a whitening agent containing milkybean extract, purified from the fruit of Burdock ( Arcium lappa ).
화장료의 주요 테마 중 하나는 피부의 기미, 주근깨 등을 없애거나, 이들의 생성을 억제하여 피부를 하얗게 하는 미백 화장료이다. 최근에는 여러 식물자원 성분들이 피부생리에 미치는 영향에 대한 연구가 활발히 이루어지고 있으며, 이로부터 안정성이 우수하고, 피부미백 효과가 뛰어난 물질들이 개발되고 있다.One of the main themes of cosmetics is whitening cosmetics that whiten the skin by eliminating blemishes, freckles, etc., or suppressing their production. Recently, studies on the effects of various plant resources on skin physiology have been actively conducted. From this, materials having excellent stability and excellent skin whitening effect have been developed.
사람의 피부색은 민족, 개인, 신체부위에 따라 다르지만, 피부나 모발색을 결정하는 색소는 멜라닌이다. 멜라닌 색소는 표피 기저층에 산재하는 멜라노사이트(Melanocyte)에 있어서 아미노산의 하나인 티로신(Tyrosine)을 기본으로 멜라닌 합성효소(Tyrosinase) 작용에 의해 산화, 중합하여 만들어진다. 멜라닌은 사람의 피부색을 결정할 뿐 아니라 자외선을 흡수하고 자외선 유해작용으로부터 피부를 지키는 역할을 하지만, 자외선 노출이나 염증에 의해 피부 내에 과다하게 생성되면 색소침착 현상이 일어나 기미나 주근깨의 원인이 된다.Human skin color varies according to ethnicity, individual, and body parts, but the pigment that determines skin and hair color is melanin. Melanin pigment is made by oxidizing and polymerizing by melanin synthase (Tyrosinase) action based on one of the amino acids Tyrosine in melanocytes (Melanocyte) scattered on the basement layer of the epidermis. Melanin not only determines the color of human skin, but also absorbs ultraviolet rays and protects the skin from harmful UV rays.However, melanin can cause pigmentation and freckles when excessively generated in the skin by UV exposure or inflammation.
멜라닌 세포에서의 멜라닌 생성은 외부조건, 호르몬, 사이토카인(cytokine)등 여러가지 인자의 영향을 받는다. 이중 α-멜라노사이트 자극 호르몬 (α-MSH: α-Melanocyte stimulating hormone)은 피부색소 침착에 관여하는 중요한 호르몬으로 POMC(Proopiomelanocortin) 단백질의 단백질 가수결합에 의해 생산되며, 자외선 조사나 염증 반응시 각질형성세포(Keratinocyte)에서 분비되어 멜라노사이트에 작용함으로서 색소 침착을 유발한다. 따라서 이러한 색소 침착 현상을 막기 위해서는 멜라닌 생성과정 중 일부 과정을 조절함으로써 억제할 수가 있다.Melanin production in melanocytes is influenced by several factors, including external conditions, hormones, and cytokines. Α-Melanocyte stimulating hormone (α-MSH) is an important hormone involved in skin pigmentation and is produced by protein hydrolysis of POMC (Proopiomelanocortin) protein. It is secreted from cells (Keratinocyte) and acts on melanocytes, causing pigmentation. Therefore, in order to prevent the pigmentation phenomenon, it can be suppressed by controlling some of the melanin production process.
기존의 코직산(kojic acid), 알부틴(Arbutin), 상백피 추출물 및 감초 추출물 등과 같은 미백제들은 티로시나제의 활성을 억제하는 역할을 한다. 이와 같은 작용 기작을 갖는 물질들은 티로시나제와 직접적인 상호작용을 함으로써 효과를 나타내게 되는데, 피부세포 내로의 흡수 및 멜라노좀으로의 침투가 용이하지 않을 경우 효과가 나타나기 어렵다.Conventional whitening agents such as kojic acid (arbutin), arbutin, lettuce extract and licorice extract play a role in inhibiting the activity of tyrosinase. Substances having such a mechanism of action have an effect by directly interacting with tyrosinase, and it is difficult to show an effect when absorption into skin cells and penetration into melanosomes are not easy.
따라서, 본 발명자들은 기존의 멜라닌 합성효소의 활성만을 저해하는 물질에 비하여 보다 효과적으로 미백 작용을 나타낼 수 있는 미백 화장료 조성물을 개발하고자 노력하였다. 결과, 우방자 추출물이 α-MSH에 의해 유발되는 멜라닌 대사 경로에 직접 작용함으로써 멜라닌 생성을 제어, 억제할 수 있으며, 기존의 미백제에비하여 훨씬 우수한 효과를 나타낼 뿐 아니라 미백제품으로의 적용 범위가 넓다는것을 발견하고 본 발명을 완성하였다.Therefore, the present inventors have tried to develop a whitening cosmetic composition that can exhibit a whitening effect more effectively than a substance that inhibits only the activity of the existing melanin synthase. As a result, allium extract can directly control and inhibit melanin production by directly acting on melanin metabolic pathways induced by α-MSH, showing much better effects than conventional whitening agents and broadening its application to whitening products. It was found and completed the present invention.
따라서, 본 발명의 목적은 자외선에 의해 유발되는 α-MSH의 활성을 억제하여 우수한 미백효과를 나타낼 수 있는 우방자 추출물을 함유하는 미백제를 제공하는데 있다.Accordingly, it is an object of the present invention to provide a whitening agent containing an allergy extract capable of suppressing the activity of α-MSH induced by ultraviolet rays and exhibiting an excellent whitening effect.
도 1은 멜라노사이트에서 멜라닌 합성효소의 발현에 대한 우방자추출물의 저해 효과를 나타내는 도면이다.1 is a diagram showing the inhibitory effect of the allergy extract on the expression of melanin synthase in melanocytes.
본 발명은 우방자추출물을 함유하는 미백제에 관한 것이다.The present invention relates to a whitening agent containing allium extract.
본 발명의 우방자추출물은 미백제 총 건조중량에 대하여 0.0001∼ 50.0 중량%, 바람직하게는 0.005∼ 5.0 중량%의 함량으로 함유된다.Allium extract of the present invention is contained in an amount of 0.0001 to 50.0% by weight, preferably 0.005 to 5.0% by weight based on the total dry weight of the whitening agent.
우방자는 국화과 식물인 우엉의 과실이다. 우엉은 초롱꽃목 국화과의 두해살이풀로 뿌리에 난 잎에는 길이 40㎝의 잎자루가 있으며 잎새는 심장꼴이고 뒷면에 흰 털이 있다. 2년째 또는 3년째 봄에 높이 1.5㎝의 꽃줄기를 뻗고 엉겅퀴와 비슷한 담자색의 꽃이 여러 개 핀다. 야생종은 유럽, 시베리아, 만주 등지에 자생하며, 유럽에서는 간혹 어린 잎과 뿌리를 식용으로 하고, 중국에서는 열매를 이뇨제로 쓰고 있다. 본래 식, 약용식물로 농가에서 옛부터 재배하였고, 길 주변과 산비탈 초지에서 자란다. 늦가을에 채취하고 잡질을 제거하고 햇볕에 말려 그대로 쓴다.Allies are the fruit of burdock, an Asteraceae plant. Burdock is a biennial herb of Asteraceae, with 40 cm long petiole on its root. The leaf is heart shaped with white hairs on the back. In the spring of 2nd or 3rd year, a flower stem 1.5cm in height and several purple flowers like thistle bloom. Wild species grow in Europe, Siberia, and Manchuria. In Europe, young leaves and roots are sometimes eaten, and fruit is used as a diuretic in China. Originally grown as a food and medicinal plant in farmhouses, it grows around roads and on hillsides. Collect it in late autumn, remove the debris and dry it in the sun.
본 발명에서는 상기의 성상에 적합한 우방자를 사용하였다.In the present invention, allies suitable for the above properties were used.
본 발명의 우방자추출물의 제조 방법은 다음과 같다.The manufacturing method of the allergy extract of the present invention is as follows.
우엉의 열매부분을 말린 것을 깨끗한 물로 세척한 다음 건조하여 분말화 하고, 분말화된 우방자의 건조 중량에 대하여 추출 용매로서 물, 저급알코올(메탄올, 에탄올), 물과 저급 알코올의 혼합물, 아세톤, 에틸아세테이트, 1,3-부틸렌 글리콜, 헥산, 디에틸 에테르, 노말 프로판올, 이소-프로판올, 노말-부탄올을 1∼ 15배의 양으로 가해 실온에서 1∼ 15일간 침적시켜 유효 성분을 추출한다. 이렇게 추출한 추출용액을 냉각 콘덴서가 달린 증류 장치를 이용하여 감압농축하여 목적하는 본 발명의 우방자추출물을 얻는다.The dried parts of the burdock are washed with clean water, dried and powdered. The dry weight of the powdered milkybean is extracted with water, lower alcohol (methanol and ethanol), a mixture of water and lower alcohol, acetone and ethyl as extraction solvents. Acetate, 1,3-butylene glycol, hexane, diethyl ether, normal propanol, iso-propanol and normal-butanol are added in an amount of 1 to 15 times, and the active ingredient is extracted by immersion at room temperature for 1 to 15 days. The extraction solution thus extracted is concentrated under reduced pressure using a distillation apparatus equipped with a cooling condenser to obtain the desired mate extract of the present invention.
본 발명의 우방자추출물을 함유하는 미백제는 그 제형에 있어서 특별히 한정되는 바가 없는데, 예를 들면 화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩 및 보디 오일 등과 같은 기초제품 화장료; 화운데이션, 립스틱, 마스카라, 메이크업 베이스 등과 같은 색조제품 화장료; 및 샴푸, 린스, 헤어콘디셔너, 헤어젤 등과 같은 두발제품 화장료;의 제형을 가질 수 있다.The whitening agent containing the allergy extract of the present invention is not particularly limited in the formulation, for example, cosmetics for basic products such as lotion, cream, essence, cleansing foam, cleansing water, pack and body oil; Color cosmetics such as foundation, lipstick, mascara, makeup base, etc .; And hair cosmetics such as shampoos, rinses, hair conditioners, hair gels, and the like.
다음의 실시예, 실험예, 및 제형예들은 본 발명의 내용을 설명하나 본 발명의 내용이 여기에 한정되는 것은 아니다.The following Examples, Experimental Examples, and Formulation Examples illustrate the content of the present invention, but the content of the present invention is not limited thereto.
실시예 1Example 1
정제수로 세척하고 건조시킨 다음 분말화한 우방자 가루 1Kg을 물 5L에 넣고 15∼ 40℃에서 5일간 추출한 후 300메쉬 여과포로 여과하고, 4∼ 15℃에서 7∼ 10일간 방치하여 저온 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이 추출물을 냉각 콘덴서가 달린 증류장치에서 60℃로 감압 농축하고 건조하여 60.4g(건조중량)을 얻었다.After washing with purified water and drying, 1Kg of powdered milk powder was added to 5L of water, extracted for 5 days at 15-40 ° C., filtered through 300 mesh filter cloth, left at 4-15 ° C. for 7-10 days, and then aged at low temperature. It was filtered twice by filter paper. The extract was concentrated under reduced pressure at 60 ° C. in a distillation apparatus equipped with a cooling condenser and dried to obtain 60.4 g (dry weight).
실시예 2Example 2
정제수로 세척하고 건조시킨 다음 분말화한 우방자 가루 1Kg을 10% 에탄올 5L에 넣고 냉각 콘덴서가 달린 추출기에서 3일간 추출한 후 300메쉬 여과포로 여과하고, 4∼ 15℃에서 7∼ 10일간 방치하여 저온 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이 추출물을 냉각 콘덴서가 달린 증류장치에서 60℃로 감압 농축하고 건조하여 78.6g(건조중량)을 얻었다.After washing with purified water and drying, 1Kg of powdered milk powder was added to 5L of 10% ethanol, extracted for 3 days in an extractor equipped with a cooling condenser, filtered through a 300 mesh filter cloth, and left at 4 to 15 ° C for 7 to 10 days to mature at low temperature. After filtration was performed using Whatman No. 2 filter paper. The extract was concentrated under reduced pressure at 60 ° C. in a distillation apparatus equipped with a cooling condenser and dried to obtain 78.6 g (dry weight).
실시예 3∼ 21Examples 3 to 21
하기 표 1 기재의 용매를 사용하여 실시예 2의 방법으로 추출하여 하기 표 1 기재와 같이 건조중량을 얻었다.Using the solvent described in Table 1 below to extract the method of Example 2 to obtain a dry weight as described in Table 1 below.
실험예 1Experimental Example 1
이미 제조된 우방자추출물의 멜라닌 생성 저해 효과를 측정하였다.The melanin production inhibitory effect of the already prepared allergy extract was measured.
1) 실험 방법1) Experiment Method
우방자추출물은 우방자 파우더를 1,3-부틸렌 글리콜에 고농도로 용해시키고 다시 완충용액에 희석하여 적당한 농도로 조절하여 추출물 시료액으로 만들어 사용하였다. 멜라노사이트는 마우스 유래 B-16 멜라노마(ATCC CRL 6323) 세포주를 구입하여 사용하였다. α-MSH는 10% DMSO(Dimethyl sulfoxide)에 녹여 1mM 용액으로 사용하였다. 멜라노마 세포주를 포도당 4.5 g/L, 10% 혈청 및 1% 항생제가 함유된 DMEM 배지에 접종하여 75㎠ T-플라스크에 37℃에서 배양하였다. 5% CO2조건하에서 24시간 배양한 후, 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를분리하고 75㎠ T-플라스크에 접종하여 6시간 배양하였다. 이때 세포 수는 1 × 107세포/플라스크이다. 여기에 적당 농도의 우방자추출물과 α-MSH를 MEM 배지에 희석시켜 배양된 멜라노마 세포에 처리하여 37℃에서 5일간 배양하였다. 배양한 후 배지를 수득하여 475nm에서 흡광도를 측정하여 멜라닌 생성 정도를 비교하였다.Allium extract was used to make an allium powder in high concentration in 1,3-butylene glycol, diluted in buffer solution, and then adjusted to an appropriate concentration to make an extract sample solution. Melanosite was used by purchasing a mouse-derived B-16 melanoma (ATCC CRL 6323) cell line. α-MSH was dissolved in 10% DMSO (dimethyl sulfoxide) and used as a 1 mM solution. Melanoma cell lines were inoculated in DMEM medium containing 4.5 g / L glucose, 10% serum and 1% antibiotics and incubated at 37 ° C. in a 75 cm 2 T-flask. After 24 hours of incubation under 5% CO 2 conditions, cells were treated with 0.05% Trypsin containing 0.02% EDTA, inoculated in a 75 cm 2 T-flask and incubated for 6 hours. Wherein the cell number is 1 × 10 7 cells / flask. Allium extract and α-MSH of appropriate concentration were diluted in MEM medium and treated with cultured melanoma cells and cultured at 37 ° C. for 5 days. After incubation, the medium was obtained and the absorbance was measured at 475 nm to compare the melanin production.
2) 실험 결과2) Experiment result
우방자추출물의 멜라닌 생성 저해 효과를 표 2에 나타내었다.Table 2 shows the melanin production inhibitory effect of allium extract.
* 상기 값은 3회 실시 평균값임* The above value is the average of 3 runs
우방자추출물들은 대부분 높은 저해 효과를 나타내었으며, 특히 실시예 8의70% 에탄올 추출물에서 가장 높은 저해효과를 가지고 있었다. 에탄올 및 메탄올을 추출용매로 사용한 실시예 1~ 13의 경우가 다른 용매를 사용한 실시예 보다 멜라닌 생성 억제 효과를 가지는 물질들의 용출이 상대적으로 높아, 에탄올 및 메탄올로 추출한 실시예에서 상대적으로 높은 저해효과를 나타내었다.Allium extracts showed the highest inhibitory effect, and especially the 70% ethanol extract of Example 8 had the highest inhibitory effect. In Examples 1 to 13 using ethanol and methanol as extraction solvents, the elution of substances having a melanin inhibitory effect was higher than those using other solvents. Indicated.
실험예 2Experimental Example 2
멜라노사이트에서 멜라닌 합성효소의 발현 억제 효과를 측정하였다.The inhibitory effect of melanin synthase on melanocytes was measured.
1) 실험방법1) Experiment Method
멜라노사이트는 마우스 유래 B-16 멜라노마(ATCC CRL 6323) 세포주를 구입하여 사용하였다. α-MSH는 10% DMSO(Dimethyl sulfoxide)에 녹여 1mM 용액으로 사용하였다. 멜라노마 세포주를 포도당 4.5 g/L, 10% 혈청 및 1% 항생제가 함유된 DMEM 배지에 접종하여 75㎠ T-플라스크에 37℃에서 배양하였다. 5% CO2조건하에서 24시간 배양한 후, 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를 분리하고 75㎠ T-플라스크에 접종하여 6시간 배양하였다. 이때 세포 수는 1 × 107세포/플라스크이다. 여기에 적당 농도의 우방자추출물과 α-MSH를 MEM 배지에 희석시켜 표 3에 기재한 조건으로 배양된 멜라노마 세포에 각각 처리하여 37℃에서 5일간 배양하였다. 배양한 후 세포를 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를 분리한 후 5분간 원심 분리하여 세포만을 수집하였다. 수집된 세포를 0.1% 트리톤-엑스 100(Triton-X 100)으로 분쇄한 후, 10% 트리스-글리신 겔(Tris-Glycine gel)에서 전기영동하고 0.2% 도파(DOPA) 용액으로 염색하여 멜라닌 합성효소의 생성 정도를 비교하였다.Melanosite was used by purchasing a mouse-derived B-16 melanoma (ATCC CRL 6323) cell line. α-MSH was dissolved in 10% DMSO (dimethyl sulfoxide) and used as a 1 mM solution. Melanoma cell lines were inoculated in DMEM medium containing 4.5 g / L glucose, 10% serum and 1% antibiotics and incubated at 37 ° C. in a 75 cm 2 T-flask. After 24 hours of incubation under 5% CO 2 conditions, cells were treated with 0.05% Trypsin containing 0.02% EDTA, inoculated in a 75 cm 2 T-flask and incubated for 6 hours. Wherein the cell number is 1 × 10 7 cells / flask. Here, the appropriate concentration of allium extract and α-MSH were diluted in MEM medium, and treated with melanoma cells incubated under the conditions shown in Table 3, followed by incubation at 37 ° C. for 5 days. After incubation, the cells were treated with 0.05% trypsin containing 0.02% EDTA to separate the cells, followed by centrifugation for 5 minutes to collect only the cells. The collected cells were triturated with 0.1% Triton-X 100, then electrophoresed on 10% Tris-Glycine gel and stained with 0.2% DOPA solution for melanin synthase. The degree of formation of was compared.
2)실험결과2) Experiment result
실험 결과는 도 1에 나타낸 바와 같다.The experimental result is as shown in FIG.
도 1에서 각각의 lane은 그 순서대로 세포 1, 세포 2, 세포 3 및 세포 4을 나타낸다.Each lane in Figure 1 represents Cell 1, Cell 2, Cell 3 and Cell 4 in that order.
실험 결과, 세포 (1)에 비해, α-MSH를 처리한 세포 (2)의 티로시아나제 단백질량이 증가하였고, α-MSH와 우방자추출물을 함께 처리한 세포 (4)의 경우 α-MSH만을 처리한 세포 (2)보다 티로시나아제 단백질량이 크게 감소하였다. 따라서, 우방자추출물은 α-MSH 처리에 의한 티로시나아제 단백질의 증가를 억제함을 알 수 있다.As a result, compared with the cell (1), the amount of tyrosianase protein of the cell (2) treated with α-MSH was increased, and only the α-MSH was used for the cell (4) treated with both α-MSH and allergy extract. The amount of tyrosinase protein was significantly reduced compared to the treated cells (2). Therefore, it can be seen that the sperm extract inhibits the increase of tyrosinase protein by α-MSH treatment.
실험예 3Experimental Example 3
이미 제조된 우방자추출물의 피브로블라스트(fibroblast) 세포에 대한 독성 여부를 측정하였다.Toxicity of fibroblast cells of the prepared ovarian extract was measured.
1) 실험 방법1) Experiment Method
피브로블라스트 세포는 마우스 유래 NIH/3T3(ATCC CRL 1658) 세포주를 구입하여 사용하였다. 피브로블라스트 세포주를 포도당 4.5 g/L, 10% 혈청 및 1% 항생제가 함유된 DMEM 배지에 접종하여 75㎠ T-플라스크에 37℃에서 배양한다. 5% CO2조건하에서 24시간 배양한 후, 0.02% EDTA가 함유된 0.05% 트립신(Trypsin)을 처리하여 세포를 분리한 후 96-웰-플라스크에 접종하여 6시간 배양하였다. 이때 세포 수는 1 × 104세포/웰이다. 여기에 적당 농도의 우방자추출물을 첨가하여 12시간 배양하였다. 배양한 후, MTT(3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolin bromide) 용액(5㎎/㎖)을 웰에 10㎕ 첨가하여 4시간 배양하고, DMSO(Dimethyl sulfoxide) 용액 100㎕를 첨가한 후, OD 570nm에서 흡광도를 측정하여 세포의 생존율을 비교하였다.Fibroblast cells were purchased from a mouse-derived NIH / 3T3 (ATCC CRL 1658) cell line. Fibroblast cell lines are inoculated in DMEM medium containing 4.5 g / L glucose, 10% serum and 1% antibiotic and incubated at 37 ° C. in a 75 cm 2 T-flask. After incubation for 24 hours under 5% CO 2 condition, cells were isolated by treatment with 0.05% Trypsin containing 0.02% EDTA, and then inoculated in a 96-well-flask and incubated for 6 hours. Wherein the cell number is 1 × 10 4 cells / well. An allium extract of an appropriate concentration was added thereto and incubated for 12 hours. After incubation, 10 μl of MTT (3- (4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolin bromide) solution (5 mg / ml) was added to the wells and incubated for 4 hours, followed by DMSO (dimethyl sulfoxide). ) 100 μl of the solution was added, and then the absorbance was measured at 570 nm to compare the viability of the cells.
2) 실험결과2) Experiment result
실험 결과는 표 4에 나타내었다.The experimental results are shown in Table 4.
- 세포에 대한 독성 판정-Determination of toxicity to cells
생존률 70% 이하 - 중독성,Survival below 70%-addictive,
70% 초과 80% 이하 - 경독성,Greater than 70% and less than 80%-mild toxicity,
80% 초과 90% 이하 - 미독성,Greater than 80% and less than 90%-non-toxic,
90% 초과 - 무독성Over 90%-non-toxic
이상의 실험결과, 우방자 추출물 첨가 배양시 대부분 미독성으로 세포자극이 거의 없는 것으로 나타났다.As a result of the above experiment, it was found that the cell stimulation was almost non-toxic in the culture of the addition of the allergy extract.
이하 상기한 실험예들의 결과를 근거로 하여 실시예 8에서의 우방자추출물을 함유하는 화장료를 조성하여 제시한다. 그러나, 본발명의 조성물을 하기의 제형예들로 한정하고자 하는 것은 아니다.Hereinafter, based on the results of the above experimental examples, to present a cosmetic composition containing the allergy extract in Example 8. However, it is not intended to limit the composition of the present invention to the following formulation examples.
제형예 1. 유연화장수(스킨로션)Formulation Example 1 Softening Cosmetic (Skin Lotion)
하기의 표와 같이 우방자 추출물을 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.As shown in the following table, the softening lotion containing the alligator extract was prepared according to a conventional method.
제형예 2. 수렴화장수Formulation Example 2. Converging Cosmetic Water
하기의 표와 같이 우방자 추출물을 함유하는 수렴화장수를 통상의 방법에 따라 제조하였다.As shown in the following table, astringent cosmetics containing allium extract were prepared according to a conventional method.
제형예 3. 영양화장수Formulation Example 3. Nutrients
하기의 표와 같이 우방자 추출물을 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.As shown in the following table, nutritious longevity containing allium extract was prepared according to a conventional method.
제형예 4. 영양크림Formulation Example 4. Nutrition Cream
하기의 표와 같이 우방자 추출물을 함유하는 영양크림을 통상의 방법에 따라 제조하였다.Nutritious cream containing allergy extract as shown in the following table was prepared according to a conventional method.
제형예 5. 맛사지크림Formulation Example 5. Massage Cream
하기의 표와 같이 우방자 추출물을 함유하는 맛사지크림을 통상의 방법에 따라 제조하였다.Massage creams containing the allergy extract as shown in the following table were prepared according to a conventional method.
제형예 6. 에센스Formulation Example 6. Essence
하기의 표와 같이 우방자 추출물을 함유하는 에센스를 통상의 방법에 따라 제조하였다.Essences containing allium extract as shown in the following table were prepared according to a conventional method.
제형예 7. 팩Formulation Example 7 Pack
하기의 표와 같이 우방자 추출물을 함유하는 팩을 통상의 방법에 따라 제조하였다.As shown in the following table, a pack containing the alligator extract was prepared according to a conventional method.
본 발명의 우방자 추출물을 함유하는 미백제는 α-MSH에 의해 유발되는 멜라닌 대사 경로에 직접 작용함으로써, 멜라닌 생성을 제어, 억제하여 우수한 미백효과를 나타낼 뿐 아니라, 미백제품으로의 적용 범위가 넓다.The whitening agent containing the alligator extract of the present invention acts directly on the melanin metabolic pathway induced by α-MSH, thereby controlling and inhibiting melanin production, thereby exhibiting excellent whitening effect, and a wide range of application to whitening products.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000076871A KR20020046615A (en) | 2000-12-15 | 2000-12-15 | Skin whitening composition containing arctium lappa extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000076871A KR20020046615A (en) | 2000-12-15 | 2000-12-15 | Skin whitening composition containing arctium lappa extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020046615A true KR20020046615A (en) | 2002-06-21 |
Family
ID=27682138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000076871A KR20020046615A (en) | 2000-12-15 | 2000-12-15 | Skin whitening composition containing arctium lappa extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20020046615A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053680A1 (en) * | 2003-12-03 | 2005-06-16 | Beiersdorf Ag | Combination of 2,3-dibenzylbutyrolactone and licochalcone-a |
KR100619459B1 (en) * | 2006-05-22 | 2006-09-07 | 대건엔지니어링(주) | Floodgate for waterways |
KR101258991B1 (en) * | 2011-04-29 | 2013-04-26 | 그린텍이십일 주식회사 | Preparation method of arctigenin including fermentation of microorganism in medium containing arctium lappa l. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990079378A (en) * | 1998-04-04 | 1999-11-05 | 서경배 | Cosmetics containing natural products that are effective in treating and preventing acne |
KR20000045575A (en) * | 1998-12-30 | 2000-07-25 | 유상옥 | Antioxidant cosmetic composition containing the seed extract of arctium lappa |
JP2000290162A (en) * | 1999-04-06 | 2000-10-17 | Nisshin Oil Mills Ltd:The | Cosmetic |
-
2000
- 2000-12-15 KR KR1020000076871A patent/KR20020046615A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990079378A (en) * | 1998-04-04 | 1999-11-05 | 서경배 | Cosmetics containing natural products that are effective in treating and preventing acne |
KR20000045575A (en) * | 1998-12-30 | 2000-07-25 | 유상옥 | Antioxidant cosmetic composition containing the seed extract of arctium lappa |
JP2000290162A (en) * | 1999-04-06 | 2000-10-17 | Nisshin Oil Mills Ltd:The | Cosmetic |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053680A1 (en) * | 2003-12-03 | 2005-06-16 | Beiersdorf Ag | Combination of 2,3-dibenzylbutyrolactone and licochalcone-a |
KR100619459B1 (en) * | 2006-05-22 | 2006-09-07 | 대건엔지니어링(주) | Floodgate for waterways |
KR101258991B1 (en) * | 2011-04-29 | 2013-04-26 | 그린텍이십일 주식회사 | Preparation method of arctigenin including fermentation of microorganism in medium containing arctium lappa l. |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
KR20150139688A (en) | The Extract Of The Citrus grandis Osbeck Having Skin Whitening Activity And Cosmetic Composition Containing The Same | |
KR101773456B1 (en) | Method for preparing complex fermented extract of crude drugs and cosmetic composition comprising the same | |
KR20090056521A (en) | Cosmetic composition for skin-aging protection and wrinkle improvement comprising the extract of nephelium lappaceum and litchi chinensis sonn as active ingredient | |
KR102032873B1 (en) | Antioxidant and moisturizing cosmetic composition | |
KR101525873B1 (en) | Cosmetic composition containing Manufacturing method and Cultured wild Ginseng Roots, Hedysarum ussuriensis, Sophora flavescens and Adenophora triphylla by two-stage fermentation for improving skin | |
KR20120003238A (en) | Composition of skin external application for skin whitening containing extract of flower and fruit of broussonetia kazinoki | |
KR100441596B1 (en) | cosmetic composition containing plant extract complex | |
KR100638056B1 (en) | Skin whitening composition containing the fruit extracts of forsythia suspensa | |
KR20200009195A (en) | A cosmetic composition comprising ligustrum lucidum extract | |
KR102612017B1 (en) | Composition for skin improvement comprising multiple extract | |
KR20170136969A (en) | Method for preparing natural extract using sugars | |
KR100914963B1 (en) | Composition for skin whitening comprising the extract of angelica dahurica, prunus mume, pinellia ternata, and artemisiae anomalae | |
KR102632084B1 (en) | Cosmetic composition for anti-oxidation, skin whitening, and improving of skin wrinkle containing Sanguisorba officinalis extract | |
KR20020046615A (en) | Skin whitening composition containing arctium lappa extracts | |
KR100789634B1 (en) | Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation | |
KR20100088463A (en) | Cosmetic composition for whitening the skin comprising the extract of aronia melanocarpa as active ingredient | |
KR100467501B1 (en) | A cosmetic composite | |
KR101695781B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of nursery spiraea | |
KR102223368B1 (en) | Cosmetic composition for skin | |
KR102567315B1 (en) | Cosmetic composition for gray hair containing fermented extracts of natural ingredients | |
KR20010110001A (en) | Cosmetics composition containing Psoralea corylifolia L. extracts | |
KR102119823B1 (en) | A cosmetic composition comprising morus bombycis extract | |
KR102006665B1 (en) | Anti-oxidant, anti-inflammatory, whitening and moisturizing cosmetic composition comprising the mixed herbal extract of silver weed, heather, and milk thistle as an active ingredient and preparation method of the same | |
KR102412907B1 (en) | Composition for skin whitening and improving skin wrinkle comprising Codonopsis lanceolata bud extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |